Φορτώνει......
Interferon-β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity
AIMS: To determine CYP2C19 and CYP2D6 activity in patients with multiple sclerosis (MS) before and during interferon (IFN)-β treatment. METHODS: CYP2C19 and CYP2D6 activities were assessed using the probe drugs mephenytoin and debrisoquine, respectively. Urinary mephenytoin (S/R) and debrisoquine (d...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Blackwell Science Inc
2003
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1884353/ https://ncbi.nlm.nih.gov/pubmed/12919185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2003.01859.x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|